Q-omics provides the consensus-scored DEFB104A profile across patient tissues and cancer cell-line models. DEFB104A expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, DEFB104A is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, DEFB104A RNA expression shows 3,203 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LIHC, HNSC, and ESCA as cancer lineages where DEFB104A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB104A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB104A survival associations across molecular data types. DEFB104A RNA expression shows survival associations in the most cancer types (5), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB104A RNA expression–survival associations across cancer types. High DEFB104A expression shows unfavorable associations in LIHC, KIRC, KIRP and LGG, but favorable associations in HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for DEFB104A RNA expression.
This table summarizes DEFB104A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB104A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB104A shows lower tumor expression in HNSC. The HNSC box plot shows higher DEFB104A RNA expression in normal versus tumor tissue (log2 FC = −0.232, t-test p = .013).
This table shows molecular features associated with DEFB104A in patient tissues and cancer cell lines. In patient samples, DEFB104A shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB104A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT.
